



CONTEMPORARY CLINICAL QUESTIONS on HPV-Related Diseases and Vaccination

2ND EDITION

ABRIDGED VERSION

REFERENCES

REFERENCES

1. International Agency for Research on Cancer. Cervical Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Available at: <http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp> Accessed January/8, 2015.
2. National Advisory Committee on Immunization. Update on Human Papillomavirus (HPV) Vaccines. 2012.
3. Merck Canada Ltd. Gardasil product monograph. July 4 2006.
4. Merck Canada Inc. Gardasil-9 Product Monograph. July 30 2015.
5. GlaxoSmithKline Inc. Cervarix Product Monograph. November 25 2014.
6. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. *Vaccine* 2006 Aug 21;24 Suppl 3:S42-51.
7. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. *CMAJ* 2001 Apr 3;164(7):1017-1025.
8. Dickinson JA, Stankiewicz A, Popadiuk C, Pogany L, Onysko J, Miller AB. Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006. *BMC Public Health* 2012 Nov 16;12:992-2458-12-992.
9. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol* 1999 Sep;189(1):12-19.
10. Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. *Cancer J* 2003 Sep-Oct;9(5):348-359.
11. Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? *J Pathol* 2014 Dec;234(4):431-435.
12. International Agency for Research on Cancer. IARC Monographs - 100B: Human Papillomaviruses. 2012; Available at: <http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-11.pdf> Accessed January/12, 2015.
13. Canadian Cancer Society's Advisory Committee on Cancer Statistics, Canadian Cancer Society. *Canadian Cancer Statistics* 2014. 2014.
14. Mosavi-Jarrahi A, Kliewer EV. Cervical cancer incidence trends in Canada: a 30-year population-based analysis. *J Obstet Gynaecol Can* 2013 Jul;35(7):620-626.
15. de Sanjose S, Bruni L, Alemany L. HPV in genital cancers (at the exception of cervical cancer) and anal cancers. *Presse Med* 2014 Oct 30;43(12P2):e423-e428.
16. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. *PLoS One* 2013 Jul 17;8(7):e68329.
17. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. *J Natl Cancer Inst* 2013 Feb 6;105(3):175-201.
18. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. *J Clin Oncol* 2011 Nov 10;29(32):4294-4301.
19. Forte T, Niu J, Lockwood GA, Bryant HE. Incidence trends in head and neck cancers and human papillomavirus (HPV)-associated oropharyngeal cancer in Canada, 1992-2009. *Cancer Causes Control* 2012 Aug;23(8):1343-1348.
- 20a. Nichols AC, Dhaliwal SS, Palma DA, Basmaji J, Chapeskie C, Dowthwaite S, et al. Does HPV type affect outcome in oropharyngeal cancer? *J Otolaryngol Head Neck Surg* 2013 Feb 1;42:9-0216-42-9.
- 20b. Nichols AC, Palma DA, Dhaliwal SS, Tan S, Theuer J, Chow W, et al. The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population. *Curr Oncol* 2013 Aug;20(4):212-219.
21. Shack L, Lau HY, Huang L, Doll C, Hao D. Trends in the incidence of human papillomavirus-related noncervical and cervical cancers in Alberta, Canada: a population-based study. *CMAJ* Open 2014 Jul 22;2(3):E127-32.

22. Campisi P, Hawkes M, Simpson K, Canadian Juvenile Onset Recurrent Respiratory Papillomatosis Working Group. The epidemiology of juvenile onset recurrent respiratory papillomatosis derived from a population level national database. *Laryngoscope* 2010 Jun;120(6):1233-1245.
23. Marra F, Ogilvie G, Colley L, Kliewer E, Marra CA. Epidemiology and costs associated with genital warts in Canada. *Sex Transm Infect* 2009 Apr;85(2):111-115.
24. Kliewer EV, Demers AA, Elliott L, Lotocki R, Butler JR, Brisson M. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. *Sex Transm Dis* 2009 Jun;36(6):380-386.
25. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. *Vaccine* 2006 Aug 31;24 Suppl 3:53/11-25.
26. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. *Cancer Epidemiol Biomarkers Prev* 2005 Feb;14(2):467-475.
27. Miralles-Guri C, Bruni L, Cubilla AL, Castellsague X, Bosch FX, de Sanjose S. Human papillomavirus prevalence and type distribution in penile carcinoma. *J Clin Pathol* 2009 Oct;62(10):870-878.
28. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. *Vaccine* 2006 Aug 21;24 Suppl 3:S26-34.
29. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. *Int J Cancer* 2007 Aug 1;121(3):621-632.
30. Giuliano, A., Joura, E., Iversen, O.E., Bautista, O., Chen, J., Moeller, E., Ritter, M., Luxembourg, A. Efficacy of a Novel Nine-valent HPV L1 Vaccine Against Disease Irrespective of HPV Type (Poster). 2014.
31. Castellsague, X., Saah, A., Luxembourg, A., Sings, H.L., Velicer, C. Potential Impact of a Nine-Valent (9v) Vaccine on Human Papillomavirus (HPV)-Related Cervical Disease in Women Aged 16 to 45 Years, by Region (Poster). 2014.
32. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. *Lancet* 2005 Sep 17-23;366(9490):991-998.
33. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. *Vaccine* 2006 Aug 31;24 Suppl 3:S26-34.
34. Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. *Infect Agent Cancer* 2012 Dec 29;7(1):38-9378-7-38.
35. Alemany L, Saunier M, Tinoco L, Quiros B, Alvarado-Cabrero I, Alejo M, et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. *Eur J Cancer* 2014 Nov;50(16):2846-2854.
36. Seoud M, Tjalma WA, Ronsse V. Cervical adenocarcinoma: moving towards better prevention. *Vaccine* 2011 Nov 15;29(49):9148-9158.
37. Pirog EC, Lloveras B, Molijn A, Tous S, Guimera N, Alejo M, et al. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. *Mod Pathol* 2014 Dec;27(12):1559-1567.
38. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. *J Infect Dis* 2010 Dec 15;202(12):1789-1799.
39. Dunne E. Prevalence of HPV infection among men: A systematic review of the literature. *The journal of infectious diseases* 2006;194(8):1044.
40. Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. *Vaccine* 2006 Aug 21;24 Suppl 3:S52-61.
41. Sellors JW, Mahony JB, Kaczorowski J, Lytwyn A, Bangura H, Chong S, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. *CMAJ* 2000 Sep 5;163(5):503-508.
42. Healey SM, Aronson KJ, Mao Y, Schlecht NF, Mery LS, Ferenczy A, et al. Oncogenic human papillomavirus infection and cervical lesions in aboriginal women of Nunavut, Canada. *Sex Transm Dis* 2001 Dec;28(12):694-700.

43. Ogilvie GS, Cook DA, Taylor DL, Rank C, Kan L, Yu A, et al. Population-based evaluation of type-specific HPV prevalence among women in British Columbia, Canada. *Vaccine* 2013 Feb 4;31(7):1129-1133.
44. Goggin, P., Coutlee, F., Mathieu-Chartier, S., Lambert, G., Gilca, V., Sauvageau, C. Prevalence of genital HPV infection in women aged 18-29, in the post-vaccination period, Québec, Canada. 2015 December 2015.
45. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. *Lancet* 2011 Mar 12;377(9769):932-940.
46. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, et al. Updating the natural history of human papillomavirus and anogenital cancers. *Vaccine* 2012 Nov 20;30 Suppl 5:F24-33.
47. Sehnal B, Dusek L, Cibula D, Zima T, Halaska M, Driak D, et al. The relationship between the cervical and anal HPV infection in women with cervical intraepithelial neoplasia. *J Clin Virol* 2014 Jan;59(1):18-23.
48. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Jr, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med* 2011 Oct 27;365(17):1576-1585.
49. Steben M, Louchini R, Duarte-Franco E. High risk of anal cancer in individuals treated for anal condyloma in a population-based transversal study, Québec (Canada), 1990-1999. In: Program and abstracts of the 18th International Society for Sexually Transmitted Disease Research, June 28– July 1, 2009. London, UK.
50. Alemany L, Saunier M, Alvarado-Cabrero I, Quiros B, Salmeron J, Shin HR, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. *Int J Cancer* 2015 Jan 1;136(1):98-107.
51. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. *Int J Cancer* 2009 Apr 1;124(7):1626-1636.
52. Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsague X, Laporte L, et al. HPV DNA, E6/E7 mRNA, and p16(INK4a) detection in head and neck cancers: a systematic review and meta-analysis. *Lancet Oncol* 2014 Nov;15(12):1319-1331.
53. Fakhry C, D'Souza G. Discussing the diagnosis of HPV-OSCC: common questions and answers. *Oral Oncol* 2013 Sep;49(9):863-871.
54. Rettig E, Kiess AP, Fakhry C. The role of sexual behavior in head and neck cancer: implications for prevention and therapy. *Expert Rev Anticancer Ther* 2015 Jan;15(1):35-49.
55. Lin BM, Wang H, D'Souza G, Zhang Z, Fakhry C, Joseph AW, et al. Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma. *Cancer* 2013 Oct 1;119(19):3462-3471.
56. D'Souza G, Cullen K, Bowie J, Thorpe R, Fakhry C. Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. *PLoS One* 2014 Jan 24;9(1):e86023.
57. Beachler DC, Abraham AG, Silverberg MJ, Jing Y, Fakhry C, Gill MJ, et al. Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. *Oral Oncol* 2014 Dec;50(12):1169-1176.
58. Auluck A, Walker BB, Hislop G, Lear SA, Schuurman N, Rosin M. Population-based incidence trends of oropharyngeal and oral cavity cancers by sex among the poorest and underprivileged populations. *BMC Cancer* 2014 May 5;14:316-2407-14-316.
59. Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. *Oral Oncol* 2014 May;50(5):380-386.
60. McDonald JT, Johnson-Obaseki S, Hwang E, Connell C, Corsten M. The relationship between survival and socio-economic status for head and neck cancer in Canada. *J Otolaryngol Head Neck Surg* 2014 Jan 14;43:2-0216-43-2.
61. Hemminki K, Dong C, Frisch M. Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands. *Eur J Cancer Prev* 2000 Dec;9(6):433-437.
62. Sinha P, Logan HL, Mendenhall WM. Human papillomavirus, smoking, and head and neck cancer. *Am J Otolaryngol* 2012 Jan-Feb;33(1):130-136.
63. Kreimer AR, Villa A, Nyitray AG, Abrahamsen M, Papenfuss M, Smith D, et al. The epidemiology of oral HPV infection among a multinational sample of healthy men. *Cancer Epidemiol Biomarkers Prev* 2011 Jan;20(1):172-182.

64. Pierce Campbell CM, Kreimer AR, Lin HY, Fulp W, O'Keefe MT, Ingles DJ, et al. Long-term Persistence of Oral Human Papillomavirus Type 16: The HPV Infection in Men (HIM) Study. *Cancer Prev Res (Phila)* 2015 Jan 9.
65. Public Health Agency of Canada. Canadian Guidelines on Sexually Transmitted Infections. 2014; Available at: http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-5-5-eng.php#t_02c_2 Accessed February/7, 2015.
66. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005 Mar-Apr;55(2):74-108.
67. Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. *Vaccine* 2006 Aug 31;24 Suppl 3:S3/S2-61.
68. Castellsague X, Munoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. *J Natl Cancer Inst Monogr* 2003;(31)(31):20-28.
69. Roura E, Castellsague X, Pawlita M, Travier N, Waterboer T, Margall N, et al. Smoking as a major risk factor for cervical cancer and pre-cancer: results from the EPIC cohort. *Int J Cancer* 2014 Jul 15;135(2):453-466.
70. La Vecchia C, Boccia S. Oral contraceptives, human papillomavirus and cervical cancer. *Eur J Cancer Prev* 2014 Mar;23(2):110-112.
71. Wang SS, Zuna RE, Wentzensen N, Dunn ST, Sherman ME, Gold MA, et al. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. *Cancer Epidemiol Biomarkers Prev* 2009 Jan;18(1):113-120.
72. Fehr MK, Baumann M, Mueller M, Fink D, Heinzl S, Imesch P, et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. *J Gynecol Oncol* 2013 Jul;24(3):236-241.
73. Schwartz LM, Castle PE, Follansbee S, Borgonovo S, Fetterman B, Tokugawa D, et al. Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men. *J Infect Dis* 2013 Dec 1;208(11):1768-1775.
74. Bekkers RL, Massuger LF, Bulten J, Melchers WJ. Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. *Rev Med Virol* 2004 Mar-Apr;14(2):95-105.
75. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. *J Clin Virol* 2005 Mar;32 Suppl 1:S16-24.
76. Abramson AL, Nouri M, Mullooly V, Fisch G, Steinberg BM. Latent Human Papillomavirus infection is comparable in the larynx and trachea. *J Med Virol* 2004 Mar;72(3):473-477.
77. Broker TR, Jin G, Croom-Rivers A, Bragg SM, Richardson M, Chow LT, et al. Viral latency--the papillomavirus model. *Dev Biol (Basel)* 2001;106:443-51; discussion 452-3, 465-75.
78. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. *Clin Sci (Lond)* 2006 May;110(5):525-541.
79. Xi LF, Demers GW, Koutsky LA, Kiviat NB, Kuypers J, Watts DH, et al. Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. *J Infect Dis* 1995 Sep;172(3):747-755.
80. Theiler RN, Farr SL, Karon JM, Paramsothy P, Viscidi R, Duerr A, et al. High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. *Obstet Gynecol* 2010 Jun;115(6):1150-1158.
81. Gravitt PE. Evidence and impact of human papillomavirus latency. *Open Virol J* 2012;6:198-203.
82. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. *J Natl Cancer Inst* 2005 Jul 20;97(14):1072-1079.
83. Bleeker MC, Hogewoning CJ, Voorhorst FJ, van den Brule AJ, Snijders PJ, Starink TM, et al. Condom use promotes regression of human papillomavirus-associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. *Int J Cancer* 2003 Dec 10;107(5):804-810.
84. Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. *J Infect Dis* 2005 Jan 15;191(2):182-192.
85. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, et al. Regression of low-grade squamous intra-epithelial lesions in young women. *Lancet* 2004 Nov 6-12;364(9446):1678-1683.

86. Public Health Agency of Canada. Canada Communicable Disease Report: Statement on human papillomavirus vaccine. 2007 February;33 ACS-2. Available at: <http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/07vol33/acs-02/index-eng.php> Accessed December/15, 2015.
87. Stanley M. Immune responses to human papillomavirus. *Vaccine* 2006 Mar 30;24 Suppl 1:S16-22.
88. Parada R, Morales R, Giuliano AR, Cruz A, Castellsague X, Lazcano-Ponce E. Prevalence, concordance and determinants of human papillomavirus infection among heterosexual partners in a rural region in central Mexico. *BMC Infect Dis* 2010 Jul 28;10:223-2334-10-223.
89. Reiter PL, Pendergraft WF,3rd, Brewer NT. Meta-analysis of human papillomavirus infection concordance. *Cancer Epidemiol Biomarkers Prev* 2010 Nov;19(11):2916-2931.
90. Burchell AN, Coutlee F, Tellier PP, Hanley J, Franco EL. Genital transmission of human papillomavirus in recently formed heterosexual couples. *J Infect Dis* 2011 Dec 1;204(11):1723-1729.
91. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, et al. Condom use and the risk of genital human papillomavirus infection in young women. *N Engl J Med* 2006 Jun 22;354(25):2645-2654.
92. Burchell AN, Richardson H, Mahmud SM, Trottier H, Tellier PP, Hanley J, et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. *Am J Epidemiol* 2006 Mar 15;163(6):534-543.
93. Solomon D, Schiffman M, Tarone R, ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. *J Natl Cancer Inst* 2001 Feb 21;93(4):293-299.
94. Sherman ME, Solomon D, Schiffman M, ASCUS LSIL Triage Study Group. Qualification of ASCUS. A comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study. *Am J Clin Pathol* 2001 Sep;116(3):386-394.
95. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. *N Engl J Med* 1998 Feb 12;338(7):423-428.
96. Jamison JH, Kaplan DW, Hamman R, Eagar R, Beach R, Douglas JM, Jr. Spectrum of genital human papillomavirus infection in a female adolescent population. *Sex Transm Dis* 1995 Jul-Aug;22(4):236-243.
97. Davidson M, Schnitzer PG, Bulkow LR, Parkinson AJ, Schloss ML, Fitzgerald MA, et al. The prevalence of cervical infection with human papillomaviruses and cervical dysplasia in Alaska Native women. *J Infect Dis* 1994 Apr;169(4):792-800.
98. Kjaer SK, Svare EI, Worm AM, Walboomers JM, Meijer CJ, van den Brule AJ. Human papillomavirus infection in Danish female sex workers. Decreasing prevalence with age despite continuously high sexual activity. *Sex Transm Dis* 2000 Sep;27(8):438-445.
99. Young TK, McNicol P, Beauvais J. Factors associated with human papillomavirus infection detected by polymerase chain reaction among urban Canadian aboriginal and non-aboriginal women. *Sex Transm Dis* 1997 May;24(5):293-298.
100. Ho GY, Kadish AS, Burk RD, Basu J, Palan PR, Mikhail M, et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. *Int J Cancer* 1998 Oct 29;78(3):281-285.
101. Wang PD, Lin RS. Risk factors for cervical intraepithelial neoplasia in Taiwan. *Gynecol Oncol* 1996 Jul;62(1):10-18.
102. Thomas DB, Ray RM, Pardthaisong T, Chutivongse S, Koetsawang S, Silpisornkosol S, et al. Prostitution, condom use, and invasive squamous cell cervical cancer in Thailand. *Am J Epidemiol* 1996 Apr 15;143(8):779-786.
103. Kjaer SK, de Villiers EM, Dahl C, Engholm G, Bock JE, Vestergaard BF, et al. Case-control study of risk factors for cervical neoplasia in Denmark. I: Role of the "male factor" in women with one lifetime sexual partner. *Int J Cancer* 1991 Apr 22;48(1):39-44.
104. de Visser RO, Smith AM. When always isn't enough: implications of the late application of condoms for the validity and reliability of self-reported condom use. *AIDS Care* 2000 Apr;12(2):221-224.
105. Warner L, Clay-Warner J, Boles J, Williamson J. Assessing condom use practices. Implications for evaluating method and user effectiveness. *Sex Transm Dis* 1998 Jul;25(6):273-277.
106. Harper DM, Demars LR. Primary strategies for HPV infection and cervical cancer prevention. *Clin Obstet Gynecol* 2014 Jun;57(2):256-278.

107. McGraw SL, Ferrante JM. Update on prevention and screening of cervical cancer. *World J Clin Oncol* 2014 Oct 10;5(4):744-752.
108. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuid A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. *Lancet* 2004 Nov 13-19;364(9447):1757-1765.
109. DeCarolis E. 9vHPV Vaccine Dose Formulation. 2014 12 10.
110. Australian Drug Evaluation Committee, Therapeutic Goods Act 1989. Commonwealth of Australia Gazette. 2006(GN 25):1523-1527.
111. Australian Government, Ministry of Health, Therapeutic Goods Administration. Gardasil Update. 2013; Available at: <https://www.tga.gov.au/alert/gardasil-quadrivalent-human-papillomavirus-vaccine> Accessed January/15, 2015.
112. European Medicines Agency. Gardasil Product Information. 2006 Sep 20a.
113. European Centre for Disease Prevention and Control. Introduction of HPV vaccine in EU countries - an update. 2012; Available at: http://www.ecdc.europa.eu/en/publications/Publications/20120905_GUI_HPV_vaccine_update.pdf Accessed January/15, 2015.
114. European Centre for Disease Prevention. HPV Vaccination in EU countries: review of new evidence. 2014; Available at: http://www.ecdc.europa.eu/en/activities/sciadvicelayouts/forms/Review_DispForm.aspx?List=a3216f4c-f040-4f51-9f77-a96046dbfd72&ID=758 Accessed January/15, 2015.
115. US Food and Drug Administration: Vaccines, Blood and Biologics. Gardasil-9. December 2014; Available at: <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm426445.htm> Accessed February/16, 2015.
116. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. *Pediatrics* 2006 Nov;118(5):2135-2145.
117. Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. *J Natl Cancer Inst* 2013 Apr 3;105(7):469-474.
118. Garland SM. The Australian experience with the human papillomavirus vaccine. *Clin Ther* 2014 Jan 1;36(1):17-23.
119. Osborne SL, Tabrizi SN, Brotherton JM, Cornall AM, Wark JD, Wrede CD, et al. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. *Vaccine* 2015 Jan 1;33(1):201-208.
120. Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. *Br J Cancer* 2014 May 27;110(11):2804-2811.
121. Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. *Br J Cancer* 2014 Oct 28;111(9):1824-1830.
122. Mahmud SM, Kliewer EV, Lambert P, Bozat-Emre S, Demers AA. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada. *J Clin Oncol* 2014 Feb 10;32(5):438-443.
123. Steben M, Ouhoumane N, Rodier C, Brassard P. Epidemiology of genital warts among individuals covered by the public drug plan in Quebec: Impact of HPV vaccination. Abstract presented at 29th International Papillomavirus Conference and Clinical Workshop. August 21-25 2014. Seattle, WA, USA.
124. Young EJ, Tabrizi SN, Brotherton JM, Wark JD, Pyman J, Saville M, et al. Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study). *BMC Cancer* 2013 Jun 19;13:296-2407-13-296.
125. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. *BMC Med* 2013 Oct 22;11:227-7015-11-227.
126. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. *Sex Transm Infect* 2009 Dec;85(7):499-502.

127. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. *Lancet* 2011 Jun 18;377(9783):2085-2092.
128. Ogilvie GS, Naus M, Money DM, Dobson SR, Miller D, Kraiden M, et al. Reduction in cervical dysplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis. *Int J Cancer* 2015 Mar 6.
129. Howlett RI, Miller AB, Pasut G, Mai V. Defining a strategy to evaluate cervical cancer prevention and early detection in the era of HPV vaccination. *Prev Med* 2009 Jan 9.
130. Kliewer EV, Demers AA, Brisson M, Alberto Severini A, Lotocki R, Elias B, et al. The Manitoba Human Papillomavirus vaccine surveillance and evaluation system. *Statistics Canada. Catalogue No.82-003-XPE: Health Reports* 2010(Vol. 21, no. 2).
131. Wong CA, Saraiya M, Hariri S, Eckert L, Howlett RI, Markowitz LE, et al. Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. *Vaccine* 2011 Jan 29;29(5):878-885.
132. Lu B, Kumar A, Castellsague X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. *BMC Infect Dis* 2011 Jan 12;11:13-2334-11-13.
133. Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmeron J, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04- adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. *Lancet* 2014 Sep 1.
134. Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borja PC, Sanchez N, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04- adjuvanted vaccine. *Hum Vaccin Immunother* 2014 Aug;10(8):2147-2162.
135. Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. *Br J Cancer* 2011 Jun 28;105(1):28-37.
136. Luna J, Plata M, Gonzalez M, Correa A, Maldonado I, Nossa C, et al. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil in adult women. *PLoS One* 2013 Dec 31;8(12):e83431.
137. Moreira,E.,Joura,E.,Van Damme,P.,Schilling,A.,Kosalaksapa,P.,Uva,L.,Martin,J.,Luxembourg,A. Safety and Tolerability of a Novel 9-Valent HPV Virus-like Particle Vaccine (Poster). 2014 2014.
138. Luxembourg, A.,Christensen, S.,Restrepo,J.A.,McNeil,S.,Kjeld-Petersen,L.,Maansson,R.,Shields,C. Immunogenicity and Safety of a 9-Valent HPV Vaccine in Prior Quadrivalent HPV Vaccine Recipients (Poster at IPV Conference). 2014.
139. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. *N Engl J Med* 2015 Feb 19;372(8):711-723.
140. Centres for Disease Control and Prevention- Morbidity and Mortality. Human Papillomavirus Vaccination Coverage Among Adolescents, 2007–2013, and Postlicensure Vaccine Safety Monitoring, 2006–2014 — United States Weekly Report July 26 2013 Weekly / Vol. 62 / No. 29. 2014; Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6329a3.htm> Accessed April/15, 2015.
141. De Vincenzo R, Conte C, Ricci C, Scambia G, Capelli G. Long-term efficacy and safety of human papillomavirus vaccination. *Int J Womens Health* 2014 Dec 3;6:999-1010.
142. World Health Organization: Global Advisory Committee on Vaccine Safety, 11–12 december 2013. *Weekly epidemiological record Relevé épidémiologique hebdomadaire*. 2014;No. 7, 2014, 89:53-60.
143. Lehtinen M, Herrero R, Mayaud P, Barnabas R, Dillner J, Paavonen J, et al. Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. *Vaccine* 2006 Aug 21;24 Suppl 3:S233-41.
144. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04- adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. *Lancet Oncol* 2012 Jan;13(1):89-99.
146. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. *N Engl J Med* 2007 May 10;356(19):1915-1927.

147. Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical intraepithelial neoplasia (CIN2-3)? *Gynecol Oncol* 2013 Aug;130(2):264-268.
148. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. *BMJ* 2012 Mar 27;344:e1401.
149. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. *Hum Vaccin* 2009 Oct;5(10):696-704.
150. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. *Lancet* 2009 Jul 25;374(9686):301-314.
151. Castellsague X, Naud P, Chow SN, Wheeler CM, Gernar MJ, Lehtinen M, et al. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. *J Infect Dis* 2014 Aug 15;210(4):517-534.
152. Fisher WA, Kohut T, Salisbury CM, Salvadori MI. Understanding human papillomavirus vaccination intentions: comparative utility of the theory of reasoned action and the theory of planned behavior in vaccine target age women and men. *J Sex Med* 2013 Oct;10(10):2455-2464.
153. Ahsaini M, Tahiri Y, Tazi MF, Elammari J, Mellas S, Khallouk A, et al. Verrucous carcinoma arising in an extended giant condyloma acuminatum (Buschke-Lowenstein tumor): a case report and review of the literature. *J Med Case Rep* 2013 Dec 19;7:273-1947-7-273.
154. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. *BMJ* 2009 Oct 8;339:b3884.
155. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. *J Infect Dis* 2011 Aug 1;204(3):372-376.
156. Burchell AN, Rodrigues A, Moravan V, Tellier PP, Hanley J, Coutlee F, et al. Determinants of prevalent human papillomavirus in recently formed heterosexual partnerships: a dyadic-level analysis. *J Infect Dis* 2014 Sep 15;210(6):846-852.
157. Public Health Agency of Canada. NACI Update on the recommended HPV vaccine immunization schedule. 2015:1-31. Available at: http://publications.gc.ca/collections/collection_2015/aspc-phac/HP40-128-2014-eng.pdf Accessed December/15, 2015
158. Institut Nationale de Sante Publique du Québec. La vaccination des pre-adolescents contre les virus du papillome humain (VPH) au Québec: deux ou trois doses? 2013; Available at: http://www.inspq.qc.ca/pdf/publications/1683_VaccinPreAdoVPHQc_2ou3Doses.pdf Accessed January/15, 2015.
159. Gilca V, Sauvageau C. Immunogenicity of one and two doses of Gardasil in 9-10 year old girls and the effect of a booster dose of Gardasil or Cervarix given three years later. 2013;WHO Consultation Meeting.
160. Gilca V, Sauvageau C, Boulianne N, De Serres G, Couillard M, Krajdin M, et al. Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule. *Hum Vaccin Immunother* 2014;10(8):2438-2445.
161. Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. *Hum Vaccin Immunother* 2014 May;10(5):1155-1165.
162. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajdin M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. *JAMA* 2013 May 1;309(17):1793-1802.
163. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. *Hum Vaccin* 2011 Dec;7(12):1374-1386.

164. Lazcano-Ponce E, Stanley M, Munoz N, Torres L, Cruz-Valdez A, Salmeron J, et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. *Vaccine* 2014 Feb 3;32(6):725-732.
165. Office federal de la sante publique (OFSP) et commission fédérale pour les vaccination. Plan de vaccination suisse 2012 - Directives et recommandations. 2012.
166. Public Health England. HPV Vaccination Programme, change from 3 to 2 doses. 2014; Available at: <https://www.gov.uk/government/publications/schedule-change-from-3-to-2-doses-in-the-hpv-vaccination-programme> Accessed January/15, 2015.
167. European Medicines Agency. Recommendations for HPV Vaccine. 2014; Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp Accessed January/15, 2015.
168. European Medicines Agency. Committee for Medicinal Products for Human Use: Assessment Report. 2014; Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000703/WC500167949.pdf Accessed January/15, 2015.
169. World Health Organization. Comprehensive Cervical Cancer Control: A Guide to Essential Practice - Second Edition. 2014; Available at: <http://www.who.int/reproductivehealth/publications/cancers/cervical-cancer-guide/en/> Accessed January/7, 2015.
170. Ministère de la Santé et des Services sociaux. Protocole d'immunisation du Québec. 6e édition. 2014; Available at: http://publications.msss.gouv.qc.ca/acrobat/f/documentation/piq/piq_complet.pdf Accessed December/26, 2014.
171. BC Centre for Disease Control. Human Papillomavirus (HPV) Vaccine Two-Dose Schedule: Q & A Document. 2014; Available at: http://www.immunizebc.ca/sites/default/files/graphics/2_dose_hpv_program_qa_final_oct_15_20151.pdf Accessed January/15, 2015.
172. Wright TC, Van Damme P, Schmitt HJ, Meheus A. Chapter 14: HPV vaccine introduction in industrialized countries. *Vaccine* 2006 Aug 21;24 Suppl 3:S122-31.
173. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. *Vaccine* 2009 Jan 22;27(4):581-587.
174. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K, et al. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. *Hum Vaccin* 2011 Sep;7(9):958-965.
175. Rioux M, Garland A, Webster D, Reardon E. HPV positive tonsillar cancer in two laser surgeons: case reports. *J Otolaryngol Head Neck Surg* 2013 Nov 18;42:54-0216-42-54.
176. Bargman H. Laser-generated Airborne Contaminants
. *The Journal of clinical and aesthetic dermatology* 2011 February;4(2):56-57.
177. Brace MD, Stevens E, Taylor S, Butt S, Sun Z, Hu L, et al. `The air that we breathe inverted question mark: assessment of laser and electrosurgical dissection devices on operating theater air quality. *J Otolaryngol Head Neck Surg* 2014 Oct 13;43(1):39.
178. Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. *Vaccine* 2006 Aug 31;24 Suppl 3:S3/52-61.
179. Centres for Disease Control and Prevention. Morbidity and Mortality Weekly Report (August 2014): Human Papillomavirus Vaccination Recommendations from the Advisory Committee on Immunization Practices. 2014 (August); Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6305a1.htm?s_cid=rr6305a1_w Accessed February/16, 2015.
180. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. *Lancet Oncol* 2012 Jan;13(1):100-110.
181. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. *Br J Cancer* 2006 Dec 4;95(11):1459-1466.
182. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. *Lancet* 2006 Apr 15;367(9518):1247-1255.

183. Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, et al. Long-term study of a quadrivalent human papillomavirus vaccine. *Pediatrics* 2014 Sep;134(3):e657-65.
184. Koutsky LA, Harper DM. Chapter 13: Current findings from prophylactic HPV vaccine trials. *Vaccine* 2006 Aug 21;24 Suppl 3:S114-21.
185. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. *Vaccine* 2006 Aug 21;24 Suppl 3:S106-13.
186. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. *Ann Intern Med* 2005 Mar 1;142(5):333-341.
187. International Agency for Research on Cancer: 22nd International Papillomavirus Conference; Vancouver, 2005.
188. Zimet GD, Mays RM, Sturm LA, Ravert AA, Perkins SM, Juliar BE. Parental attitudes about sexually transmitted infection vaccination for their adolescent children. *Arch Pediatr Adolesc Med* 2005 Feb;159(2):132-137.
189. Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L. Acceptability of human papillomavirus immunization. *J Womens Health Gend Based Med* 2000 Jan-Feb;9(1):47-50.
190. Ritvo P, Irvine J, Klar N, Wilson K, Brown L, Bremner KE, et al. A Canadian national survey of attitudes and knowledge regarding preventive vaccines. *J Immune Based Ther Vaccines* 2003 Nov 5;1(1):3.
191. Lazcano-Ponce E, Rivera L, Arillo-Santillan E, Salmeron J, Hernandez-Avila M, Munoz N. Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. *Arch Med Res* 2001 May-Jun;32(3):243-247.
192. Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. *Int J STD AIDS* 2003 May;14(5):300-306.
193. Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. *J Low Genit Tract Dis* 2004 Jul;8(3):188-194.
194. Olshen E, Woods ER, Austin SB, Luskin M, Bauchner H. Parental acceptance of the human papillomavirus vaccine. *J Adolesc Health* 2005 Sep;37(3):248-251.
195. Giles M, Garland S. A study of women's knowledge regarding human papillomavirus infection, cervical cancer and human papillomavirus vaccines. *Aust N Z J Obstet Gynaecol* 2006 Aug;46(4):311-315.
196. Zimet GD, Liddon N, Rosenthal SL, Lazcano-Ponce E, Allen B. Chapter 24: Psychosocial aspects of vaccine acceptability. *Vaccine* 2006 Aug 21;24 Suppl 3:S201-9.
197. Zimet GD, Perkins SM, Sturm LA, Bair RM, Juliar BE, Mays RM. Predictors of STI vaccine acceptability among parents and their adolescent children. *J Adolesc Health* 2005 Sep;37(3):179-186.
198. Bair, R.M., Mays, R.M., Sturm, L.M. & Zimet, G.D. The acceptability of STD vaccination to Latino parents. *Journal of Adolescent Health* 2005;36(2):123-124.
199. Canadian Immunization Committee. Recommendations for Human Papillomavirus Immunization Programs. 2014 April 2014.
200. Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. *JAMA* 2014 Feb 12;311(6):597-603.
201. Stanley M. Prospects for new human papillomavirus vaccines. *Curr Opin Infect Dis* 2010 Feb;23(1):70-75.
202. Kosalaraksa P, Mehlsen J, Vesikari T, Forsten A, Helm K, Van Damme P, et al. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age. *Pediatr Infect Dis J* 2015 Jun;34(6):627-634.
203. Health Canada. Canadian immunization guide (Canadian Medical Association). 2007;7th edition.
204. Brown MR, Noffsinger A, First MR, Penn I, Husseinzadeh N. HPV subtype analysis in lower genital tract neoplasms of female renal transplant recipients. *Gynecol Oncol* 2000 Nov;79(2):220-224.
205. Zhang L, Epstein JB, Poh CF, Berean K, Lam WL, Zhang X, et al. Comparison of HPV infection, p53 mutation and allelic losses in post-transplant and non-posttransplant oral squamous cell carcinomas. *J Oral Pathol Med* 2002 Mar;31(3):134-141.

206. Roka S, Rasoul-Rockenschaub S, Roka J, Kirnbauer R, Muhlbacher F, Salat A. Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression. *Transpl Int* 2004 Aug;17(7):366-369.
207. Al-Osman A, Perry JB, Birek C. Extensive papillomatosis of the palate exhibiting epithelial dysplasia and HPV 16 gene expression in a renal transplant recipient. *J Can Dent Assoc* 2006 May;72(4):331-334.
208. Hinten F, Meeuwis KA, van Rossum MM, de Hullu JA. HPV-related (pre)malignancies of the female anogenital tract in renal transplant recipients. *Crit Rev Oncol Hematol* 2012 Nov;84(2):161-180.
209. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. *J Clin Invest* 2006 May;116(5):1167-1173.
210. Roden R, Wu TC. Preventative and therapeutic vaccines for cervical cancer. *Expert Rev Vaccines* 2003 Aug;2(4):495-516.
211. Stanley MA. Genital human papillomavirus infections: current and prospective therapies. *J Gen Virol* 2012 Apr;93(Pt 4):681-691.
212. Stern PL, van der Burg SH, Hampson IN, Broker TR, Fiander A, Lacey CJ, et al. Therapy of human papillomavirus-related disease. *Vaccine* 2012 Nov 20;30 Suppl 5:F71-82.
213. Haedicke J, Iftner T. Human papillomaviruses and cancer. *Radiother Oncol* 2013 Sep;108(3):397-402.
214. Rosales R, Rosales C. Immune therapy for human papillomaviruses-related cancers. *World J Clin Oncol* 2014 Dec 10;5(5):1002-1019.
215. Bravo IG, Felez-Sanchez M. Papillomaviruses: viral evolution, cancer and evolutionary medicine. *Evol Med Public Health* 2015 Jan 28.
216. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. *Obstet Gynecol* 2006 Jan;107(1):18-27.
217. Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. *Hum Vaccin* 2009 Oct;5(10):696-704.
218. Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. *Int J Cancer* 2012 Jul 1;131(1):106-116.
219. Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. *Clin Infect Dis* 2012 Apr;54(7):891-898.
220. Hildesheim A, Markowitz L, Avila MH, Franceschi S. Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines. *Vaccine* 2006 Aug 21;24 Suppl 3:S227-32.
221. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. *J Natl Cancer Inst* 2011 Oct 5;103(19):1444-1451.
222. Lin CJ, Zimmerman RK, Nowalk MP, Huang HH, Raviotta JM. Randomized controlled trial of two dosing schedules for human papillomavirus vaccination among college age males. *Vaccine* 2014 Feb 3;32(6):693-699.
223. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. *Lancet* 2006 Apr 15;367(9518):1247-1255.
224. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. *Lancet Infect Dis* 2012 Oct;12(10):781-789.
225. Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. *Hum Vaccin* 2007 Jul-Aug;3(4):109-115.
226. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. *J Infect Dis* 2009 Apr 1;199(7):926-935.

227. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. *J Infect Dis* 2009 Apr 1;199(7):936-944.
228. Public Health Agency of Canada. What Everyone Should Know About Human Papilloavirus (HPV): Questions and Answers. 2012; Available at: <http://www.phac-aspc.gc.ca/std-mts/hpv-vph/hpv-vph-qaqr-eng.php> Accessed January/12, 2015.
229. Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. *Vaccine* 2006 Aug 21;24 Suppl 3:S171-7.
230. Frazer IH, Cox JT, Mayeaux EJ, Jr, Franco EL, Moscicki AB, Palefsky JM, et al. Advances in prevention of cervical cancer and other human papillomavirus-related diseases. *Pediatr Infect Dis J* 2006 Feb;25(2 Suppl):S65-81, quiz S82.
231. Howlett RI, Marrett LD, Innes MK, Rosen BP, McLachlin CM. Decreasing incidence of cervical adenocarcinoma in Ontario: is this related to improved endocervical Pap test sampling? *Int J Cancer* 2007 Jan 15;120(2):362-367.
232. Canadian Partnership Against Cancer. HPV Testing. 2012; Available at: http://www.cancerview.ca/cv/portal/Home/PreventionAndScreening/PSPProfessionals/PSScreeningAndEarlyDiagnosis/AnticipatoryScience/HPVTesting?_afLoop=48771022763000&jsessionid=tr0IZZHyuFU4cYLABhMZf-mOb_Qnes1viy4Bu5H6NAkmKy87DVxb%21816818526&lang=en&_afWindowMode=0&_adf.ctrl-state=1cea75w21p_4 Accessed January/20, 2015.
233. World Health Organization. Position Paper on HPV Vaccine; Summary. 2014; Available at: http://www.who.int/immunization/position_papers/pp_hpv_oct2014_summary.pdf Accessed January/15, 2015.
234. Liu S, Semenciv R, Mao Y. Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. *CMAJ* 2001 Apr 17;164(8):1151-1152.
235. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. *Int J Cancer* 2007 Feb 15;120(4):885-891.
236. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, et al. Comprehensive control of human papillomavirus infections and related diseases. *Vaccine* 2013 Dec 31;31 Suppl 7:H1-31.
237. Salit IE, Lytwyn A, Raboud J, Sano M, Chong S, Diong C, et al. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. *AIDS* 2010 Jun 1;24(9):1307-1313.
238. Patel J, Salit IE, Berry MJ, de Pokomandy A, Nathan M, Fishman F, et al. Environmental scan of anal cancer screening practices: worldwide survey results. *Cancer Med* 2014 Aug;3(4):1052-1061.
239. Coutlee F, de Pokomandy A, Franco EL. Epidemiology, natural history and risk factors for anal intraepithelial neoplasia. *Sex Health* 2012 Dec;9(6):547-555.
240. Canadian Dental Association. Oral Cancer Fact Sheet. Available at: http://www.cda-adc.ca/en/oral_health/complications/diseases/oral_cancer.asp Accessed January/11, 2015.
241. U.S. Preventive Services Task Force. Oral Cancer Screening: Recommendation Summary. Available at: <http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/oral-cancer-screening?ds=1&s=oral%20screening> Accessed January/11, 2015.
242. Brocklehurst P, Kujan O, O'Malley LA, Ogdan G, Shepherd S, Glenny AM. Screening programmes for the early detection and prevention of oral cancer. *Cochrane Database Syst Rev* 2013 Nov 19;11:CD004150.
243. Soderlund-Strand A, Kjellberg L, Dillner J. Human papillomavirus type-specific persistence and recurrence after treatment for cervical dysplasia. *J Med Virol* 2014 Apr;86(4):634-641.
244. Morrell S, Qian L. A whole-population profile of HPV testing as a test of cure for high-grade cervical dysplasia in NSW, Australia. *J Med Screen* 2014 Sep;21(3):151-162.
245. Kang WD, Oh MJ, Kim SM, Nam JH, Park CS, Choi HS. Significance of human papillomavirus genotyping with high-grade cervical intraepithelial neoplasia treated by a loop electrosurgical excision procedure. *Am J Obstet Gynecol* 2010 Jul;203(1):72.e1-72.e6.
246. CoHIPP trial (Colposcopy vs. HPV testing to identify persistent cervical pre-cancers post treatment); results at recruitment and randomization. International Papillomavirus Conference

; 2014; Seattle, USA; 2014.

247. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. *J Low Genit Tract Dis* 2013 Apr;17(5 Suppl 1):S56-63.
248. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. *Obstet Gynecol* 2013 Apr;121(4):829-846.
249. Kang WD, Kim CH, Cho MK, Kim JW, Cho HY, Kim YH, et al. HPV-18 is a poor prognostic factor, unlike the HPV viral load, in patients with stage IB-IIA cervical cancer undergoing radical hysterectomy. *Gynecol Oncol* 2011 Jun 1;121(3):546-550.
250. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. *Clin Infect Dis* 2002 Nov 1;35(9):1127-1134.
251. D'Souza G, Wiley DJ, Li X, Chmiel JS, Margolick JB, Cranston RD, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. *J Acquir Immune Defic Syndr* 2008 Aug 1;48(4):491-499.
252. Nielsen A, Munk C, Kjaer SK. Trends in incidence of anal cancer and highgrade anal intraepithelial neoplasia in Denmark, 1978–2008. *Int J Cancer*. 2012;130(5):1168–1173.
253. Jin F, Stein AN, Conway EL, Regan DG, Law M, Brotherton JM, et al. Trends in anal cancer in Australia, 1982–2005. *Vaccine* 2011 Mar 9;29(12):2322-2327.
254. Robinson D, Coupland V, Moller H. An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. *Br J Cancer*. 2009;100(3):527–531.
255. Crowe E, Pandeya N, Brotherton JM et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. *BMJ* 2014;348:g1458.
256. Mesher, D, K.Soldan, R.Howell-Jones, K.Panwar, P.Manyenga, M. Jit, S.Beddows, O.N.Gill: Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation. *J Clin Pathol*. 2015 Feb;68(2):135-40.
257. Hariri S, Markowitz LE, Bennett NM, Niccolai LM, Schafer S, Bloch K, et al. Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012. *Emerg Infect Dis* 2015 Sep;21(9):1557-1561.
258. Ali H, Donovan B, Wand H, Read TRH, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. *Bmj-Brit Med J* 2013;346:f2032.
259. Graham DM, Isaranuwatthai W, Habbous S, de Oliveira C, Liu G, Siu LL, et al. A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer. *Cancer* 2015 Jun 1;121(11):1785-1792.
260. Winer RL, Hughes JP, Feng Q, Xi LF, Lee SK, O'Reilly SF, et al. Prevalence and risk factors for oncogenic human papillomavirus infections in high-risk mid-adult women. *Sex Transm Dis* 2012 Nov;39(11):848-856.
261. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009–2010. *JAMA* 2012; 307:693–703.
262. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. *J Clin Oncol* 2011; 29:4294–301.
263. Beachler DC, D'Souza G, Sugar EA, Xiao W, Gillison ML. Natural history of anal vs oral HPV infection in HIV-infected men and women. *J Infect Dis* 2013 Jul 15;208(2):330-339.
264. Nyitray AG, Carvalho da Silva RJ, Baggio ML, Smith D, Abrahamsen M, Papenfuss M, et al. Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in men study. *J Infect Dis* 2011 Dec 1;204(11):1711-1722.
265. Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. *Pediatr Infect Dis J* 2015 Sep;34(9):983-991.
266. Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States. *MMWR Morb Mortal Wkly Rep* 2014 Jul 25;63(29):620-624.